Aref A Bin Abdulhak1, Kevin F Kennedy2, Sanjaya Gupta2,3, Michael Giocondo2,3, Brian Ramza2,3, Alan P Wimmer4,5. 1. Division of Cardiovascular Disease, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USA. 2. Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, 4330 Wornall Road, Suite 2000, Kansas City, MO, 64111, USA. 3. Department of Medicine, School of Medicine, University of Missouri-Kansas City, Kansas City, MO, USA. 4. Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, 4330 Wornall Road, Suite 2000, Kansas City, MO, 64111, USA. awimmer@saint-lukes.org. 5. Department of Medicine, School of Medicine, University of Missouri-Kansas City, Kansas City, MO, USA. awimmer@saint-lukes.org.
Abstract
PURPOSE: Effective intraprocedural anticoagulation is considered essential to minimize the risk of thromboembolism in catheter ablation (CA) of atrial fibrillation (AF). The effect of interrupted apixaban on intraprocedural heparin dosing requirements and levels of achieved anticoagulation with heparin has not been well studied. The purpose of the present study was to compare heparin administration and activated clotted times (ACTs) for patients undergoing CA for AF treated with interrupted apixaban before the procedure with patients on uninterrupted warfarin. METHODS: Consecutive patients undergoing CA for AF treated with interrupted apixaban or uninterrupted warfarin were prospectively enrolled. Heparin administration determined by a standard protocol and normalized to patient weight and procedure duration, as well as rapidity, and degree of anticoagulation with heparin (as measured by mean ACT, peak ACT, time to ACT ≥300 s, and time to ACT ≥350 s) were compared between the groups. RESULTS: Forty-eight patients were enrolled (25 apixaban and 23 warfarin). Heparin administered by bolus (51.3 ± 21.5 vs 27.8 ± 9.6 units/kg/h; p < 0.001) and mean heparin drip rate (25.3 ± 3.6 vs 20.7 ± 2.4 units/kg/h; p < 0.001) were significantly higher in the apixaban group compared to the warfarin group. Despite greater heparin administration, apixaban patients achieved a significantly lower mean ACT (332.3 ± 17.0 vs 384.5 ± 53.9; p < 0.001) and peak ACT (369.5 ± 22.6 vs 432.3 ± 75.8, p < 0.001) compared to the warfarin group. The time to ACT ≥350 s (66.7 ± 35.8 vs 26.9 ± 34.0; p < 0.001) was significantly longer for apixaban-treated patients. Outcome differences persisted after analysis using linear models and Cox proportional hazard regression with adjustment for propensity scores. CONCLUSIONS: A standard intraprocedural heparin protocol results in delayed and lower levels of anticoagulation as measured by the ACT for interrupted apixaban-treated patients in comparison to those on uninterrupted warfarin during CA of AF.
PURPOSE: Effective intraprocedural anticoagulation is considered essential to minimize the risk of thromboembolism in catheter ablation (CA) of atrial fibrillation (AF). The effect of interrupted apixaban on intraprocedural heparin dosing requirements and levels of achieved anticoagulation with heparin has not been well studied. The purpose of the present study was to compare heparin administration and activated clotted times (ACTs) for patients undergoing CA for AF treated with interrupted apixaban before the procedure with patients on uninterrupted warfarin. METHODS: Consecutive patients undergoing CA for AF treated with interrupted apixaban or uninterrupted warfarin were prospectively enrolled. Heparin administration determined by a standard protocol and normalized to patient weight and procedure duration, as well as rapidity, and degree of anticoagulation with heparin (as measured by mean ACT, peak ACT, time to ACT ≥300 s, and time to ACT ≥350 s) were compared between the groups. RESULTS: Forty-eight patients were enrolled (25 apixaban and 23 warfarin). Heparin administered by bolus (51.3 ± 21.5 vs 27.8 ± 9.6 units/kg/h; p < 0.001) and mean heparin drip rate (25.3 ± 3.6 vs 20.7 ± 2.4 units/kg/h; p < 0.001) were significantly higher in the apixaban group compared to the warfarin group. Despite greater heparin administration, apixabanpatients achieved a significantly lower mean ACT (332.3 ± 17.0 vs 384.5 ± 53.9; p < 0.001) and peak ACT (369.5 ± 22.6 vs 432.3 ± 75.8, p < 0.001) compared to the warfarin group. The time to ACT ≥350 s (66.7 ± 35.8 vs 26.9 ± 34.0; p < 0.001) was significantly longer for apixaban-treated patients. Outcome differences persisted after analysis using linear models and Cox proportional hazard regression with adjustment for propensity scores. CONCLUSIONS: A standard intraprocedural heparin protocol results in delayed and lower levels of anticoagulation as measured by the ACT for interrupted apixaban-treated patients in comparison to those on uninterrupted warfarin during CA of AF.
Authors: Luigi Di Biase; Dhanujaya Lakkireddy; Chintan Trivedi; Thomas Deneke; Martin Martinek; Sanghamitra Mohanty; Prasant Mohanty; Sameer Prakash; Rong Bai; Madhu Reddy; Carola Gianni; Rodney Horton; Shane Bailey; Elisabeth Sigmund; Michael Derndorfer; Anja Schade; Patrick Mueller; Atilla Szoelloes; Javier Sanchez; Amin Al-Ahmad; Patrick Hranitzky; G Joseph Gallinghouse; Richard H Hongo; Salwa Beheiry; Helmut Pürerfellner; J David Burkhardt; Andrea Natale Journal: Heart Rhythm Date: 2015-02-26 Impact factor: 6.343
Authors: David Snipelisky; Jordan C Ray; Ryan Ung; Melissa Duart; Christine Kauffman; Fred Kusumoto Journal: J Interv Card Electrophysiol Date: 2014-11-08 Impact factor: 1.900
Authors: Sai V Konduru; Aamir A Cheema; Philip Jones; Yan Li; Brian Ramza; Alan P Wimmer Journal: J Interv Card Electrophysiol Date: 2012-09-27 Impact factor: 1.900
Authors: Hakan Oral; Aman Chugh; Mehmet Ozaydin; Eric Good; Jackie Fortino; Sundar Sankaran; Scott Reich; Petar Igic; Darryl Elmouchi; David Tschopp; Alan Wimmer; Sujoya Dey; Thomas Crawford; Frank Pelosi; Krit Jongnarangsin; Frank Bogun; Fred Morady Journal: Circulation Date: 2006-08-14 Impact factor: 29.690
Authors: Luigi Di Biase; J David Burkhardt; Prasant Mohanty; Javier Sanchez; Rodney Horton; G Joseph Gallinghouse; Dhanunjay Lakkireddy; Atul Verma; Yaariv Khaykin; Richard Hongo; Steven Hao; Salwa Beheiry; Gemma Pelargonio; Antonio Dello Russo; Michela Casella; Pietro Santarelli; Pasquale Santangeli; Paul Wang; Amin Al-Ahmad; Dimpi Patel; Sakis Themistoclakis; Aldo Bonso; Antonio Rossillo; Andrea Corrado; Antonio Raviele; Jennifer E Cummings; Robert A Schweikert; William R Lewis; Andrea Natale Journal: Circulation Date: 2010-06-01 Impact factor: 29.690
Authors: Ayman A Hussein; David O Martin; Walid Saliba; Deven Patel; Saima Karim; Omar Batal; Mustafa Banna; Michelle Williams-Andrews; Minerva Sherman; Mohamed Kanj; Mandeep Bhargava; Thomas Dresing; Thomas Callahan; Patrick Tchou; Luigi Di Biase; Salwa Beheiry; Bruce Lindsay; Andrea Natale; Oussama Wazni Journal: Heart Rhythm Date: 2009-07-10 Impact factor: 6.343
Authors: Melanie Gunawardene; S Willems; B Schäffer; J Moser; R Ö Akbulak; M Jularic; C Eickholt; J Nührich; C Meyer; P Kuklik; S Sehner; V Czerner; B A Hoffmann Journal: Clin Res Cardiol Date: 2016-07-19 Impact factor: 5.460
Authors: Anene Ukaigwe; Pragya Shrestha; Paras Karmacharya; Sarah K Hussain; Soraya Samii; Mario D Gonzalez; Deborah Wolbrette; Gerald V Naccarrelli Journal: J Interv Card Electrophysiol Date: 2016-10-22 Impact factor: 1.900
Authors: Michael Hardy; Jonathan Douxfils; Anne-Sophie Dincq; Anne-Laure Sennesael; Olivier Xhaet; Francois Mullier; Sarah Lessire Journal: Front Cardiovasc Med Date: 2022-03-29